Clinical Trial Update: Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the safety and efficacy of DVS-223 SR for vasomotor symptoms associated with menopause. The study was sponsored by Wyeth, now a sub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause
• Vasomotor Symptoms

Drugs mentioned

• DVS-223 SR

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vasomotor Symptoms | Phase 3 | Status: COMPLETED